{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-25-001536","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.064694+00:00","generated_at":"2026-05-16T19:46:20.030960+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Anavex receives negative CHMP trend vote on blarcamesine MAA; plans re-examination","bullets":["CHMP issued negative trend vote on MAA for blarcamesine for early Alzheimer's; formal opinion expected December 2025.","Company intends to request re-examination upon formal adoption, including providing relevant biomarker data.","FDA advised Anavex to request a meeting to discuss Alzheimer's clinical trial results.","No change to ongoing FDA review process; company remains in dialogue with regulators."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-25-001536","json":"https://secwatch.observer/filing/0001731122-25-001536.json","markdown":"https://secwatch.observer/filing/0001731122-25-001536.md","text":"https://secwatch.observer/filing/0001731122-25-001536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225001536/0001731122-25-001536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225001536/e7038_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:46:20.030960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}